ProCE Banner Activity

PROTAC ER Degraders in ER+/HER2- MBC After ET: Novel ER-Targeting Therapy Data and a Look to the Future 

Slideset

Download these slides to gain expert insights on the current clinical trial research investigating novel PROTAC ER degrader agents for patients with ER+/HER2- MBC after disease progression on endocrine therapy. 

Released: November 19, 2024

Expiration: November 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.